ZUG, Switzerland - Pharvaris (NASDAQ:PHVS), a clinical-stage biopharmaceutical company, has announced significant findings from its Phase 2 trial of deucrictibant, a novel oral treatment for hereditary angioedema (HAE). The data will be presented at the upcoming American Academy of Allergy, Asthma, & Immunology Annual Scientific Meeting in Washington D.C. from February 23-26, 2024.
The study, known as CHAPTER-1, enrolled HAE type 1 and type 2 patients across Canada, Europe, the United Kingdom, and the United States. Participants, who were not on other prophylactic treatments and experienced at least one attack per month, received either a placebo or deucrictibant in 20 or 40 mg/day doses over 12 weeks.
Results showed a significant reduction in monthly attack rates by 84.5% for the 40 mg/day dosage and 79.3% for the 20 mg/day dosage compared to placebo. Additionally, deucrictibant decreased the occurrence of moderate and severe attacks and the use of on-demand medication. The drug was well-tolerated at both doses with no serious treatment-emergent adverse events (TEAEs) reported.
Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris, stated that deucrictibant could become a preferred option for both treating and preventing HAE attacks due to its potential to provide injectable-like efficacy and a favorable safety profile in oral form.
Deucrictibant acts by antagonizing the bradykinin B2 receptor, which is implicated in the clinical signs of an HAE attack. Pharvaris is developing two formulations of the drug: a capsule for rapid onset of activity and an extended-release tablet for sustained efficacy in prophylactic treatment.
Pharvaris is focused on developing oral bradykinin B2 receptor antagonists to treat and prevent HAE attacks, aiming to provide efficacious, safe, and easy-to-administer alternatives to current treatments.
The information in this article is based on a press release statement from Pharvaris.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.